ABSTRACT
I. Introduction The pretransplant management and evaluation of individuals with cystic fibrosis (CF) and non-CF bronchiectasis is described below. The median predicted age of survival for individuals with CF has now increased to over 37 years (1); yet despite tremendous advances in the management of CF, progressive respiratory failure remains the primary source of morbidity and mortality. Therefore, lung transplantation is an important therapeutic option for CF patients with end-stage lung disease. CF is the third most common indication for lung transplantation in adults (2), after chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), and the most common indication in the pediatric population (3). CF adults have the longest median survival of any group receiving lung transplants (2).
